|
1) Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. Science. 2005; 309: 623-6
|
|
|
|
2) Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med. 2005; 11: 791-6
|
|
|
|
|
|
3) Zhong J, Gastaminza P, Cheng G, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci USA. 2005; 102: 9294-9
|
|
|
|
|
|
4) Yi M, Villanueva RA, Thomas DL, et al. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci USA. 2006; 103: 2310-5
|
|
|
|
|
|
5) Koutsoudakis G, Kaul A, Steinmann E, et al. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. J Virol. 2006; 80: 5308-20
|
|
|
|
|
|
6) Pietschmann T, Kaul A, Koutsoudakis G, et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci USA. 2006; 103: 7408-13
|
|
|
|
|
|
7) Haqshenas G, Dong X, Ewart G, et al. A 2a/1b full-length p7 inter-genotypic chimeric genome of hepatitis C virus is infectious in vitro. Virology. 2007; 360: 17-26
|
|
|
|
|
|
8) Yi M, Ma Y, Yates J, et al. Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus. J Virol. 2007; 81: 629-38
|
|
|
|
|
|
9) Murray CL, Jones CT, Tassello J, et al. Alanine scanning of the hepatitis C virus core protein reveals numerous residues essential for production of infectious virus. J Virol. 2007; 81: 10220-31
|
|
|
|
|
|
10) Murayama A, Date T, Morikawa K, et al. The NS3 helicase and NS5B-to-3'X regions are important for efficient hepatitis C virus strain JFH-1 replication in Huh7 cells. J Virol. 2007; 81: 8030-40
|
|
|
|
|
|
11) Boulant S, Targett-Adams P, McLauchlan J. Disrupting the association of hepatitis C virus core protein with lipid droplets correlates with a loss in production of infectious virus. J Gen Virol. 2007; 88: 2204-13
|
|
|
|
|
|
12) Delgrange D, Pillez A, Castelain S, et al. Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins. J Gen Virol. 2007; 88: 2495-503
|
|
|
|
|
|
13) Evans MJ, von Hahn T, Tscherne DM, et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature. 2007; 446: 801-5
|
|
|
|
|
|
14) Zheng A, Yuan F, Li Y, et al. Claudin-6 and claudin-9 function as additional co-receptors for hepatitis C virus. J Virol. 2007; 81: 12465- 71
|
|
|
|
|
|
15) Kapadia SB, Barth H, Baumert T, et al. Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol. 2007; 81: 374-83
|
|
|
|
|
|
16) Blanchard E, Belouzard S, Goueslain L, et al. Hepatitis C virus entry depends on clathrin-mediated endocytosis. J Virol. 2006; 80: 6964-72
|
|
|
|
|
|
17) Appel N, Pietschmann T, Bartenschlager R. Mutational analysis of hepatitis C virus nonstructural protein 5A: potential role of differential phosphorylation in RNA replication and identification of a genetically flexible domain. J Virol. 2005; 79: 3187-94
|
|
|
|
|
|
18) Huang Y, Staschke K, De Francesco R, et al. Phosphorylation of hepatitis C virus NS5A nonstructural protein: a new paradigm for phos-phorylation-dependent viral RNA replication？ Virology. 2007; 364: 1-9
|
|
|
|
|
|
19) Lindenbach BD, Pragai BM, Montserret R, et al. The C terminus of hepatitis C virus NS4A encodes an electrostatic switch that regulates NS5A hyperphosphorylation and viral replication. J Virol. 2007; 81: 8905-18
|
|
|
|
|
|
20) Sakamoto H, Okamoto K, Aoki M, et al. Host sphingolipid biosynthesis as a target for hepatitis C virus therapy. Nat Chem Biol. 2005; 1: 333-7
|
|
|
|
|
|
21) Umehara T, Sudoh M, Yasui F, et al. Serine palmitoyltransferase inhibitor suppresses HCV replication in a mouse model. Biochem Biophys Res Commun. 2006; 346: 67-73
|
|
|
|
|
|
22) Ikeda M, Abe K, Yamada M, et al. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology. 2006; 44: 117-25
|
|
|
|
|
|
23) Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci USA. 2005; 102: 2561-6
|
|
|
|
|
|
24) Wang C, Gale M Jr., Keller BC, et al. Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. Mol Cell. 2005; 18: 425-34
|
|
|
|
|
|
25) O'Leary JG, Chan JL, McMahon CM, et al. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology. 2007; 45: 895-8
|
|
|
|
|
|
26) Huang H, Sun F, Owen DM, et al. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci USA. 2007; 104: 5848-53
|
|
|
|
|
|
27) Kim KH, Hong SP, Kim K, et al. HCV core protein induces hepatic lipid accumulation by activating SREBP1 and PPARgamma. Biochem Biophys Res Commun. 2007; 355: 883-8
|
|
|
|
|
|
28) Nakagawa M, Sakamoto N, Tanabe Y, et al. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins. Gastroenterology. 2005; 129: 1031-41
|
|
|
|
|
|
29) Watashi K, Ishii N, Hijikata M, et al. Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase. Mol Cell. 2005; 19: 111-22
|
|
|
|
|
|
30) Fernandes F, Poole DS, Hoover S, et al. Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B. Hepatology. 2007; 46: 1026-33
|
|
|
|
|
|
31) Robida JM, Nelson HB, Liu Z, et al. Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro. J Virol. 2007; 81: 5829-40
|
|
|
|
|
|
32) Inoue K, Umehara T, Ruegg UT, et al. Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo. Hepatology. 2007; 45: 921-8
|
|
|
|
|
|
33) Miyanari Y, Atsuzawa K, Usuda N, et al. The lipid droplet is an important organelle for hepatitis C virus production. Nat Cell Biol. 2007; 9: 1089-97
|
|
|
|
|
|
34) Kawai T, Takahashi K, Sato S, et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol. 2005; 6: 981-8
|
|
|
|
|
|
35) Meylan E, Curran J, Hofmann K, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature. 2005; 437: 1167-72
|
|
|
|
|
|
36) Gack MU, Shin YC, Joo CH, et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature. 2007; 446: 916-20
|
|
|
|
|
|
37) Malathi K, Dong B, Gale M Jr, et al. Small self-RNA generated by RNase L amplifies antiviral innate immunity. Nature. 2007; 448: 816-9
|
|
|
|
|
|
38) Arimoto K, Takahashi H, Hishiki T, et al. Negative regulation of the RIG-I signaling by the ubiquitin ligase RNF125. Proc Natl Acad Sci USA. 2007; 104: 7500-5
|
|
|
|
|